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Abstract
Background: The composition and surface structure of dietary lipids influence their intestinal degradation.
Intake of liposomes made of fractionated oat oil (LOO) is suggested to affect the digestion process and
postprandial lipemia and also induce satiety.
Objective: In the present study, the metabolic effects on plasma lipids and gut hormones related to satiety
were investigated in healthy individuals after intake of LOO, with dairy lipids as placebo.
Design: Two blinded randomized studies with crossover design were performed. In the first study, 19 subjects
consumed 35 g lipids from LOO or yoghurt in a breakfast meal. In a follow-up study, 15 women consumed 14
or 1.8 g lipids from LOO mixed in yoghurt. Blood samples were analyzed for plasma lipids, insulin, glucose,
and intestinal hormones CCK, PYY, GLP-1, and GLP-2 before and four times after the meal. Subjective
analysis of satiety was measured using a visual analog scale questionnaire. Participants recorded their food
intake during the rest of the day.
Results: Intake of 35 and 14 g lipids from LOO significantly increased plasma concentrations of CCK, GLP-
1, GLP-2, and PYY postprandially. This coincided with a prolonged elevation of triglycerides and large
cholesterol-containing particles. Non-esterified fatty acids decreased after intake of 14 and 1.8 g lipids from
LOO. The subjective sensation of satiety in women was increased 7 h after intake of 35 g lipids from LOO
without any difference in food intake. Our results indicate that intake of 14 g lipids from LOO at breakfast
substantially reduced energy intake during the rest of the day.
Conclusions: This study suggests that intake of LOO prolong lipid digestion, affect postprandial plasma lipids
and have an effect on satiety. The effect of LOO on GLP-2 indicates that intake of LOO also improve gut
health.
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F
ood structure and composition influence the
digestion rate and nutrient uptake. The presence
of fat in the distal small intestine stimulates release
of gastric hormones, slows down gastric emptying and
pancreatic secretion, and induces satiety (1 3). Dietary
fat is normally emulsified by the action of bile salts and
polar lipids, and the core lipids of micelles and emulsion
particles are accessible to the battery of pancreatic lipol-
ytic enzymes. Polar lipids in general are very surface-
active compounds (4).
Changes in the surface structure of dietary lipids,
caused by changes in the composition of the polar lipids
around the core lipids, may affect the rate by which the
core lipids are being hydrolyzed (5). Consequently,
hormone-induced satiety and postprandial plasma lipid
output can be affected by modification of the polar lipids
around the core lipids.
The gut hormones cholecystokinin (CCK), glucagon-
like peptide 1 (GLP-1), and peptide YY (PYY) are
released after a meal and influence the appetite center in
hypothalamus. CCK induces satiety in a dose-dependent
manner (6). GLP-1 is released as response to intake of
macronutrients and reduces gastric emptying (7). Dietary
fatwasreportedtobethemostpowerfulstimulantofPYY
secretion when investigating single nutrients (8). PYY is
also a key mediator of ileal brake (9).
research
food & nutrition 
Food & Nutrition Research 2014. # 2014 Lena Ohlsson et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited.
1
Citation: Food & Nutrition Research 2014, 58: 24465 - http://dx.doi.org/10.3402/fnr.v58.24465
(page number not for citation purpose)The glucagon-like peptide 2 (GLP-2) is not a satiety
hormone, but it is co-expressed with GLP-1, and acts
locally as a growth factor for the intestinal cells. Factors
stimulating the increase in postprandial GLP-2 are not
fully identified, but undigested or partly digested lipids in
the terminal ileum are suggested factors (10, 11).
Polar lipids, comprising glycerophospholipids, sphin-
golipids, and in plants also galactolipids, are major lipid
constituents in cell membranes. They represent a minor
component in our diet with an average intake of 3 5g /
day (12).
Oats contain more lipids than other cereals, and
extracted oat oil has a high concentration of polar lipids,
about 15 wt%. The main component of polar lipids in
oats is the galactolipid digalactosyldiacylglycerol
(DGDG), and 50% of the DGDG in oats contain a
hydroxyl fatty acid, 15(R)-hydroxy linoleic acid, mainly
in sn-2 position on the glycerol. The hydroxyl group is
completely esterified with another fatty acid. This acyl-
digalactosyl diacylglycerol is a natural estolide, which is
unique for oats (13 15).
Galactolipids are mainly hydrolyzed by the pancreatic
lipase related protein 2 (PLRP2), an enzyme from the
pancreatic lipase family which has been shown to be a
galactolipase (16, 17). When surface lipids contain not
only phospholipids but also galactolipids, the lipolysis of
the core triglycerides (TGs) can be affected (4). However,
the digestion of oat estolides is unknown.
We propose that after ingestion of galactolipid-rich oils
dispersed into very small liposomes, the amount of lipids
in distal parts of the small intestine will increase. The
mechanism for this may be that the very small liposomes
may cause hindrance of the lipolytic enzymes to hydro-
lyze the lipids; that is, a film rich in galactolipids will
cover the active sites of the lipases which may hamper the
rate of lipid hydrolysis. Another suggested mechanism is
that particles with a galactolipid-rich surface will be
hydrolyzed at a slower rate and leave partly undigested
and unabsorbed lipid products in distal part of the
intestine. An increasing amount of lipids in the ileum
will thereby stimulate hormonal signals of satiety and
affect postprandial lipemia at a relative low energy intake.
In order to investigate the hypothesis that galactolipid-
rich small particles will affect gastrointestinal satiety
hormones and postprandial lipemia, we have developed
processes to produce very small, stable, and uniform
liposomes from fractionated oat oil (LOO) (18, 19).
Different concentrations of LOO were given to healthy
volunteers in a breakfast meal and we investigated:
plasma levels of gastrointestinal hormones, metabolic
parameters, perceived satiety, and total energy intake
during the experimental day. We used milk fat as dairy
yoghurt as control for two reasons: because it represents a
commonly used food item in a Nordic breakfast, and
because in the few numbers of studies similar to this one
(20, 21), dairy products were used as control.
Methods
Production of LOO
The oat oil fraction used in these experiments was high in
polar lipids and obtained by controlling the concentra-
tion of ethanol, water, and sugar in different fractiona-
tion steps after ethanol extraction of oats. The lipid class
composition of the fractionated oat oil was determined
by HPLC (22). The main lipid classes are presented in
Table 1.
Very small, stable, and uniform liposomes were formed
almost spontaneously during dilution of the fractionated
oat oil in a carefully controlled composition of ethanol 
water mixture. The liposomes formedwere diluted further
in water and finally the ethanol was evaporated (19). The
final liposome preparation contained 10 wt% lipids and
90 wt% water. The volumetric average diameter of the
liposomes was 100 nm, measured by dynamic light
scattering (Zetasizer Nanoseries, Malvern Instruments).
The stability of the liposomes was investigated by
dilution 1:1 in: water; citric acid buffers pH 4, pH 3; citric
acid 1 M. It was not possible to detect any changes in
structure after 4 months in water. The stability decreased
at decreasing pH. Using 1 M citric acid, it lasted 4 days
before any changes could be seen. Thus, it is very
reasonable that these liposomes were sufficiently stable
to survive the low pH in the stomach and that they could
enter the duodenum intact.
Human studies
In the first part, 19 healthy men and women (10 women,
9 men) of mean age 42, BMI 25, were recruited through
announcements on the local intranet and advertisements.
On two occasions 10 14 days apart, they were randomly
assigned either a test- or placebo breakfast. In the second
part of the study, we enrolled 15 women of mean age 34
and BMI 24. On three occasions, the 15 women received
two doses of LOO in test breakfast or yoghurt in the
placebo breakfast.
Table 1. Lipid class composition of LOO and milk fat in placebo
yoghurt
LOO
a wt% of lipids Milk fat
b wt% of lipids
Triglycerides 40.9 95.8
Galactolipids 31.4 0.0
Phospholipids 20.0 1.1
Sterols 6.6 0.5
Others 1.3 2.6
aMeasured by HPLC.
bFrom literature (23).
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in the fasting state, and hyperlipidaemia in addition to
signs of liver or kidney disease or inflammatory activity
as indicated by raised C-reactive protein, liver tests
(bilirubin, alkaline phosphatase, gamma-glutamyl trans-
peptidase, and aminotransferases), and creatinine levels.
All participants gave their written informed consent prior
to the study. The studies were approved by the Regional
Human Ethics Committee of Lund-Malmo ¨, Sweden (Dnr
2010/18, 2011/55).
Participantsconducted food registrations in theform of
diaries over 4 days before the experiments and also of the
remainderofthedayofeachtrial.Theintakewasanalyzed
by the use of Dietist XP software with the Swedish
National Food Administration database (2008 03 06)
(Kost och Na ¨ringsdata, Sweden). Dietary intakes were
related to recommended Swedish dietary guidelines (24).
Trial setup and analysis
The breakfast meals were composed of one slice of bread
(37 g), one slice of smoked ham with 3% fat (14 g),
blackberry jam (40 g), coffee or tea without milk or sugar
and free access to water. The blackberry jam was mixed
into the placebo and test meal before serving in order to
mask any difference in taste and appearance. Both test-
and placebo yoghurt contained 35 g of lipids at a
concentration of 10 wt%. The placebo yoghurt was plain
non-flavored dairy yoghurt with 10% fat. The test
yoghurt contained three different amounts of LOO
containing 35 g lipids in the first study, and 14 and 1.8
g lipids in the follow-up study. The remaining lipids up to
35 g were from milk; the total fat concentration was 10%.
The fatty acid composition of the two lipid sources is
presented in Table 2 and the lipid classes are presented in
Table 1. A fat-free milk powder was added to the LOO in
order to balance intake of protein, calcium, and carbo-
hydrate in the meal (Table 3).
Participants arrived at 7.00 am. Blood samples from the
fore arm vein were taken before breakfast, when the
subjects had been fasting since 9.00 pm the night before.
The succeeding blood samples were taken 1, 3, 5, and 7 h
after breakfast. All blood samples were immediately
centrifuged and plasmawas kept at  708C until analysis.
The participants were not allowed to eat anything for the
following 5 h after breakfast. After blood sampling at 5 h
after breakfast, the participants were served ad libitum a
selection of pre-weighed food items (bread, egg, tomato,
red bell pepper, low-fat spread cheese, smoked ham, and
a banana) and the amounts were registered. The final
blood sample was taken 7 h after breakfast. Finally, the
participantsregisteredwhattheyatefortherestofthatday.
The blood samples were analyzed for triglycerides,
cholesterol, blood glucose, insulin, HDL and LDL cho-
lesterol, liver tests, C-reactive protein, hemoglobin, white
blood cell count, and platelet count. All analyses were
done at the Department of Clinical Chemistry, University
Hospital of Lund, Sweden using the accredited routine
methods developed by Roche Diagnostics (MSDS  
COBAS Integra†   General Chemistry). Two milliliter
EDTA-plasma with the addition of a protease inhibitor,
aprotinin (Trasylol†), were immediately frozen at  708C
for later analyses of non-esterified fatty acids (NEFAs)
(NEFA-c kit, Wako Chemicals, USA) the gut hormones
PYY, GLP-1, GLP-2, and CCK. Total PYY (3 36 and 1 
36), total GLP-1 (7 36 and 9 36) and GLP-2 were
analyzed by ELISA from Merck Millipore, Solna Sweden.
CCKwas measured by a RIA, which is entirely specific for
the bioactive CCKs in plasma (26, 27).
Subjective measurements of satiety
Participants were asked to subjectively rate their feeling
of fullness (satiety), hunger, and desire to eat on a 10-cm
visual analog scale (VAS) at each time point of blood
Table 2. Fatty acid composition of LOO and milk fat in placebo
yoghurt
LOO
a wt% of FA Milk fat
b wt% of FA
C 4:0 12:0 0.0 15.9
C 14:0 0.2 11.3
C 16:0 15.0 30.3
C 18:0 1.1 11.5
C 18:1 37.4 21.6
C 18:2 31.1 1.5
C 18:3 1.1 0.6
C 18:2 15-OH 12.4 0.0
Others 1.8 7.3
aDerived from our lipid class analysis by HPLC in combination with FA
analysis from literature (25).
bFrom literature (23).
Table 3. The composition of the whole meals from the ﬁrst part of
the study including either dairy yoghurt or LOO with milk powder
Total meal Placebo/yoghurt LOO and milk powder
Weight (g) 521 604
Energy (KJ) 2,892 3,056
Energy (Kcal) 690 730
Protein (g) 19.3 18.9
Carbohydrates (g) 65.4 65.7
Total fat (g) 38.7 43.4
Saturated fat (g) 24 9.1
Monounsaturated fat (g) 8.6 13.6
Polyunsaturated fat (g) 0.7 17.9
Cholesterol (mg) 115.1 9.8
Plant sterols (mg) 0 900
Fiber (g) 3.4 4.6
Calcium (mg) 407 443
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asapercentageona10-cmscalewhere100%meanstotally
satiety and 0 means no sensation of hunger at all.
They were also asked to report any gastrointestinal
sensation/side effect and notable difference between each
meal regarding satiety and hunger.
Statistics
Plasma values were normalized according to an averaged
blank between placebo and test meal(s). Significance of
differences, between the results obtained with the LOO
and placebo yoghurt, was examined using Student’s
paired t-test or paired ANOVA multiple measures.
Bonferroni post hoc test was carried out when significant
differences between diets were found. The calculation of
incremental area under curve (iAUC) was done using the
trapezoid rule on the period 0 5 h. The Student’s paired
t-test was used to calculate if there were any difference
between the LOO and placebo after specific time points.
Linear regression analysis was performed on the correla-
tion between caloric intake and plasma PYY concentra-
tions. All statistical analyses and calculations of iAUC
were performed with GraphPad Prism (version 5.00.
GraphPad software, San Diego, CA, USA).
Results
Study with high intake of LOO
In the first study, 19 participants ingested 410 ml LOO
containing 35g lipids or placebo meal with an equal
amount of dairy lipids (Tables 2 and 3). There were both
men and women in both groups.
Analysis of blood samples
The iAUC0 5h for plasma TG was not significantly dif-
ferent after the LOO compared to placebo; however, after
7 h the TG response was significantly higher with the
LOO meal (Fig. 1) (n 19, p 0.016).
The iAUC0 5hfor plasma glucose was significantly
decreased (n 19, p 0.03) after intake of LOO com-
pared to placebo (Fig. 2), with a significant lower
concentration of plasma glucose at all postprandial
time points (n 19, p 0.01, 0.0004, 0.01, and 0.0027).
The concentration of NEFAs in plasma was slightly
lower after LOO compared to after placebo at 1, 3, and
5 h (trends pB0.1). The plasma concentrations of total-,
HDL-, and LDL cholesterol did not change postpran-
dial. The minor fluctuations of the plasma concentrations
of cholesterol seen after placebo were not significantly
different from concentrations after LOO. We calculated
the concentration of large cholesterol-containing parti-
cles (LC particles) by subtracting HDL and LDL
cholesterol from total cholesterol. We found that the
concentration of LC particles was more evenly distrib-
uted over time after LOO and did not display any peak
concentration at 3 h as after placebo yoghurt (Fig. 3).
This difference in pattern reflects a prolonged output of
TG-rich lipoproteins and their remnants after a breakfast
with LOO compared to the placebo yoghurt.
The concentrations of the hormones PYY, GLP-1, and
CCKafterintakeofLOOwith35glipidsweresignificantly
Fig. 1. The postprandial plasma concentrations of triglycer-
ides after intake of LOO and placebo. The triglyceride
concentrations after intake of breakfast with LOO contain-
ing 35 g lipids (m) or after a placeboyoghurt (k). The arrow
at 5 h indicates intake of lunch. Data are presented as mM
TG and are mean9SEM, n 19. *Values after 7 h were
signiﬁcantly different (pB0.05).
Fig. 2. The postprandial plasma concentration of glucose
after intake of LOO and placebo. Plasma glucose after
intake of a breakfast containing LOO with 35 g lipids (m)o r
after a placebo yoghurt (k). The difference in iAUC0 5h was
signiﬁcantly lower (p 0.03) with LOO. The arrow at 5 h
indicates intake of lunch. Data are presented as mM glucose
and mean9SEM, n 19. *Values at all postprandial time
points were signiﬁcantly different (pB0.05).
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points 3, 5, and 7 h (Fig. 4a c). The iAUC0 5hfor GLP-1
and CCKwassignificantly increased after LOO compared
to placebo (p 0.028 and 0.048 respectively). CCK was
significantly increased after 3 h with LOO (p 0.019) and
GLP-1 was significantly increased after 5 h (p 0.021).
PYY, GLP-1, and CCK were significantly increased with
LOO after 7 h compared to placebo (p 0.004, 0.014, and
0.012, respectively).
The levels of PYY, GLP-1, and CCKwere significantly
higher after 5 h with LOO (Figs. 4 and 7). It is reasonable
that high levels of satiety hormones before lunch will lead
to reduced energy intake during the rest of the day.
Therefore, we investigated whether there was a correla-
tion between the concentration of the satiety hormones
just before lunch and the total energy intake on the
experimental day. In Fig. 5, the results for PYY just
before lunch (PYY5h) are plotted against the total energy
intake during the experimental day for all the participants
with completed data (both 35 g LOO and placebo). By
using these data, we derived an equation (Eq. 1). There
was a negative trend between PYY5hand total energy
during the rest of the day (Spearman r -0,247, CI-0.5255
to 0.08024, p  0.0986). When we use Eq. 1 on the PYY
results from the second study in this paper (14 g LOO vs.
placebo), it indicates that an intake of LOO containing
14 g lipids at breakfast will reduce the total energy intake
for the whole day with 7% compared to intake of the
same amount of lipids from yoghurt at breakfast. GLP-1
showed a similar trend as PYY (data not shown).
Energy Intakerest of day ¼ 2036   17:72
 PYY5th (1)
On the VAS scale formula, women reported significantly
higher satiety 7 h after intake of LOO compared to
placebo, 70% satiety after LOO vs. 58% after placebo
(n 10, p 0.0056). However, for men (n 9) we did not
find any significant differences between the meals (data
not shown).
Study with lower intake of LOO
The follow-up study on 15 women investigated the effects
from intake of two lower concentrations of LOO contain-
ing 14 and 1.8 g lipids. The meals were compensated with
fat-free milk powder to balance the intake of protein,
calcium and carbohydrate and plain non-flavored yoghurt
tobalancethetotalamountoffatto35g.Thecomposition
of the meals and study design were otherwise identical to
the first study.
Analysis of blood samples
The iAUC for TG was not different after intake of LOO
containing 14 and 1.8 g lipids compared to placebo and
there were no postprandial differences in plasma glucose
or insulin levels (data not shown). The iAUC0 5hfor
NEFAswas significantly lower after 14 g lipids from LOO
compared to placebo (p 0.024) (Fig. 6) and after 3 h the
NEFA concentration was significantly lower with 14 g
lipids from LOO compared to placebo (p 0.015). There
were no differences in plasma total, HDL or LDL
cholesterol levels after the different LOO intake and
placebo yoghurt (data not shown).
The iAUC0 5hfor PYY and CCK were significantly
higher with LOO containing 14 g lipids compared to 1.8 g
andplacebo(PYYp 0.008for14gvs.1.8gandp 0.009
for 14 g vs. placebo, for CCK p 0.007 for 14 g vs. 1.8 g
and p 0.002 for 14 g vs. placebo), whereas no signifi-
cant difference in the iAUC0 5hfor GLP-1 was observed
(Fig. 7a c). Both PYY and CCK were significantly
increased with LOO containing 14 g lipids compared to
placebo or to LOO containing 1.8 g lipids (PYYp 0.009
and p 0.008 respectively and CCK p 0.001 and
pB0.0001, respectively). GLP-1 was higher (pB0.1) or
significantly higher after 1 and 5 h with 14 g of LOO
compared to placebo (1 h p 0.043, 5 h p 0.064) and
there was a trend towards a difference between LOO with
1.8 g lipids and placebo at 3 h (p 0.09).
GLP-2 was only analyzed after a breakfast containing
LOO with 14 g lipids and placeboyoghurt. The iAUC0 5h
as well as the concentration of GLP-2 at all postprandial
time points was significantly higher after LOO compared
to placebo (iAUC0 5hp 0.002, 1 h p 0.0001, 3 h
p 0.04, 5 h p 0.017, and 7 h p 0.029) (Fig. 8).
Records of intake and side effects in both studies
The participants registered their food intake during the
ad libitum served lunch and reminder of that day. Energy
intake was 14% lower for women the rest of the day
after breakfast with LOO containing 35 g lipids compared
to placebo, but this difference was not statistically sig-
nificant. The average energy intake at lunch was similar
Fig. 3. The postprandial plasma concentration of large
cholesterol-containing particles (LC) after intake of LOO
and placebo. Plasma concentration of LC particles after
intake of a breakfast containing LOO with 35 g lipids (m)o r
after a placebo yoghurt (k). LC particles are the values for
total cholesterol with HDL and LDL subtracted. The arrow
at 5 h indicates intake of lunch. Data are presented as mM
cholesterol and mean9SEM, n 19.
Intake of liposomes made from fractionated oat oil
Citation: Food & Nutrition Research 2014, 58: 24465 - http://dx.doi.org/10.3402/fnr.v58.24465 5
(page number not for citation purpose)around 424 kcal (441 after LOO containing 35 g lipids and
407 kcal after placebo) (range 275 725 in both groups)
and not significantly different. The rest of the day was
also not different between the three different meals and
placebo in the follow-up study (data not shown).
The highest amount of LOO was not very palatable
despite the addition of jam. However, LOO containing
both 14 and 1.8 g of lipids could easily be mixed with
milk powder and yoghurt and flavored; these meals were
therefore not very different from placebo.
A few subjects reported an uncomfortable feeling in
theirgut thefirst hours afterintakeof breakfast. However,
no differencebetweenanyof thetest products and placebo
could be distinguished.
Discussion
The present work aimed to answer the question whether
intake of liposomes made of fractionated oat oil (LOO)
could affect metabolic parameters related to satiety and
postprandial plasma lipids in healthy non-obese subjects.
The LOO was given in abreakfast meal after an overnight
fast and compared to milk fat in dairy yoghurt.
The main finding was that intake of LOO significantly
increased the appetite regulating hormones PYY, GLP-1,
and CCK as well as the intestinal growth promoting
hormone GLP-2, when the dose of LOO contained 14 and
35 g of lipids.
The proportions of TG, polar lipids, and sterols, as well
as the proportion of saturated and unsaturated fatty acids
Fig. 4. The postprandial plasma concentration of PYY, GLP-1, and CCK after intake of LOO and placebo. Plasma
concentrations of gastrointestinal hormones after intake of breakfast containing LOO with 35 g lipids (m) or after a placebo
yoghurt (k). The arrow at 5 h indicates intake of lunch. Data are presented as pM and mean9SEM, n 12 19. (a) Shows PYY
and there was a signiﬁcant difference between LOO and placebo 7 h postprandially (p 0.004). (b) Shows total GLP-1 and there
was a signiﬁcant difference between LOO and placebo 5 h postprandially (p 0.028). (c) Shows CCK and there were signiﬁcant
differences between LOO and placebo after 3 and 5 h postprandially (p 0.02 and p 0.012, respectively). *Values were
signiﬁcantly different (pB0.05).
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LOO, and we can see how this reflects the postprandial
plasma lipids accordingly. With the highest dose of LOO,
we found prolonged elevated postprandial concentra-
tions of plasma TG accompanied with decreased plasma
glucose concentration. The peak concentration of TG is
significantly lower than with dairy yoghurt, which reflects
both the lower concentration of TG in LOO and also the
lower concentration of saturated fatty acids (Tables 1
and 2).
The concentration of NEFAs was lower after LOO
than with milk fat. This can be indications of medium-
and short chain fatty acids from the milk migrating as
free fatty acids and also a smaller pool of TG-rich
lipoproteins from LOO available for hydrolysis by
lipoprotein lipase, but also indicate an effect of a
hampered lipid digestion. A lowering of NEFAs is an
important and desirable effect since elevated p-NEFA
concentrations can increase the production of VLDLs
and subsequently raise LDL-C levels (28).
The prolonged TG elevation after intake of 35 g LOO
was accompanied with an increase in large cholesterol-
containing particles without any peak and a delayed
return to baseline. The nature of these cholesterol
particles was not investigated, but remnant particles
from chylomicron and VLDL are expected to dominate
at the later time intervals (29).
In general we saw very little influence of LOO and
placebo yoghurt on the plasma cholesterol levels. The
acute intake of a meal containing 35 g fat or less has a
low impact on postprandial cholesterol-rich particles,
which has been shown in similar postprandial experi-
ments (30). However, surface material from LOO and
milk fat globule membrane might influence the formation
of lipoprotein particles both in number and size and
composition differently and thereby their degradation
and uptake. In this case, the polar lipids from milk fat
seem more accessible for the degrading enzymes and for
the adsorbing surfaces than the polar lipids from LOO.
In healthy humans, the main glucose lowering effect
following a meal is the inhibition of gastric emptying and
increased insulin secretion both mediated by GLP-1. In
the first study, intake of LOO with 35 g lipids might
indicate a slower gastric emptying due to the hampered
but prolonged lipemia. However, neither the postprandial
glucose peak nor insulin appearing within the first hour
was investigated.
The prolonged lipemia is in line with a significant
increase of the intestinal hormones PYY, CCK, and
GLP-1 and sensation of fullness at later time points.
We hypothesized to find a reversed correlation between
postprandial gut hormone levels and total energy intake
during the experimental day. The levels of PYY, GLP-1,
and CCKwere surprisingly high 5 h after consumption of
LOO containing more than 14 g lipids (Figs. 4 and 7).
The trend we found between PYY concentration and
total energy intake during the rest of the day, Fig 5 and
Eq. 1, indicates a reduction of energy intake during the
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LOO compared to placebo (p 0.015). *Values after 3 h
were signiﬁcantly different (pB0.05).
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believe that we confirm other studies that show that
higher plasma concentrations of PYY between meals are
indicative of a reduction in energy intake in following
meals (31, 32). However, more investigations are required
to find out if lower doses of LOO can achieve similar
effects and if these effects remain after a long period of
time.
We found significant differences in satiety hormones
(PYY, GLP-1, and CCK) but also for other parameters
like glucose, NEFAs, and GLP-2 compared to control for
the two highest LOO doses (35 and 14 g lipids). However,
for the lowest dose of LOO (1.8 g lipids), we could not
detect any significant differences from placebo in this
study. The responses were rather similar for the two
highest doses, indicating a stepwise response rather than
a linear response. Therefore, it is of interest to perform
further studies with doses of LOO in the interval between
1.8 and 14 g lipids.
Maintaining a normal body weight is getting more and
more difficult around the world due to constant access to
energy dense food and less physical activity.
Fig. 7. The postprandial plasma concentration of PYY, GLP-1, and CCK after intake of two doses of LOO and placebo.
Plasma concentrations of gastrointestinal hormones after intake of a breakfast containing LOO with 14 g lipids (m), LOO with
1.8 g lipids ( ), or after a placebo yoghurt (k). The arrow at 5 h indicates intake of lunch. (a) Shows PYY and there were
signiﬁcant different iAUCs between LOO with 14 g lipids and placebo (p 0.009) and between LOO with 14 g and 1.8 g lipids
(p 0.008). (b) Shows total GLP-1 and the difference between LOO with14 g lipids and placebo was signiﬁcant at 1 and 5 h.
(pB0.05) and there was a trend towards a difference between LOO with 1.8 g lipids and placebo at 3 h (p 0.09). (c) Shows
CCK and there were signiﬁcant differences in iAUC0 5h between LOO with 14 g lipids and placebo (pB0.0001), and between
LOO with 14 and 1.8 g lipids (p 0.0013). Data are presented as pM and mean9SEM, n 12 15. *Values were signiﬁcantly
different (pB0.05) between 14 g and placebo; $values were signiﬁcantly different between 14 and 1.8 g LOO (pB0.05).
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regain health, energy intake must be cut down and
regular physical activity must be performed. It is often
difficult to treat obesity efficiently due to physiological
and psychological aspects. The most efficient means
available today are by performing surgical gastric bypass
and guidance by professional nutritionists. Pharmacolo-
gical drugs and intake of functional food can offer a
significant additive effect to a weight loss regime.
There are several studies addressing the issue of
increased and prolonged satiety as a means to better
control food intake (33). To add food components like
soluble fiber or protein to beverages or liquid meal to
reduce consecutive food intake has had some success (34,
35). Also, recently concentrated thylakoid membranes
from spinach leafs was suggested to promote appetite
control and weight loss (36). Intake of different fatty
acids PUFA may have effects on obesity but there is no
consensus (37).
Earlier intervention studies with Fabuless/Olibra, an
emulsion containing 40 wt% fractionated palm oil, 2.5
wt% fractionated oat oil and 57.5 wt% water, showed a
significant dose-dependent decrease in energy intake 4 h
and the following day after intake of Fabuless/Olibra in a
dairy yoghurt (20, 38, 39). These early results have been
regarded as inconclusive since positive findings regarding
reduced energy intake could not be repeated (40, 41). The
difficulties in obtaining conclusive results are believed to
be derived from factors such as eating behavior, study
design, and processing of the Fabuless-yoghurt mixture.
The lipids used in the present study do not contain
palm oil, only fractionated oat oil. The concentration of
polar lipids in LOO was considerably higher than in
Fabuless (56 vs. 2.5 lipid %). A consequence of this is that
the structure of the particles is different; the core of
liposomes (LOO) is water, while the core of the particles
in an emulsion (Fabuless) is oil (21, 42).
LOO can only be prepared when the concentration
of polar lipids are above 50 lipid %. We have invented
new procedures to prepare such liposomes (18, 19). The
resulting LOOs are very stable and can pass the stomach
without any substantial changes in the structure of the
LOO caused by the low pH. The particle size of the used
LOO was much smaller than milk fat globules, 100 vs.
1,000 nm. The positive postprandial effects are more
obvious with LOO than with Fabuless, but the long-term
effects from ingestion of LOO are not known.
We believe that due to the unique composition of the
fractionated oat oil and the structure of the LOO used
in this study, that LOO was digested differently than
the dairy emulsion. The main factors that may influence
the digestion of LOO compared to milk fat here is a
physically changed surface structure affecting the hydro-
lysis of the lipids, or a different hydrolysis pattern of the
galactolipids compared to the phospholipids by pancrea-
tic lipases, and the influence of the size of the particles.
The unique structure of the oat galactolipids, the
estolides, may also contribute to the observed delayed
digestion. The outcome of the delayed/hampered diges-
tion of LOO is an increased exposure of the distal ileum
to digested or partly digested LOO compared to milk fat.
Conclusions
We conclude that intake of LOO significantly affected
postprandial TG, LC particles, glucose and the appetite
regulating hormones CCK, PYY, GLP-1 as well as the
sensation of satiety. Intake of LOO also significantly
stimulated the growth promoting gut hormone GLP-2.
These postprandial consentaneous results on healthy
individuals argue for possible long-term effects from
intake of LOO on satiety and food intake and possible
also on gut health. A well-controlled long-term study
aiming at satiety, weight control, and gut health on
suitable subjects is therefore warranted.
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